Analystreport

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Cantor Fitzgerald from $700.00 to $760.00. They now have an "overweight" r

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com